ANEMIA COMMENTARY: Recent Changes in Anemia Management: The Kidney Disease Improving Global Outcomes (KDIGO) Anemia Guideline versus the Canadian Society of Nephrology (CSN)

Harwood, Lori RN(EC), PhD (candidate)
Wazny, Lori BScPharm, PharmD
Wilson, Jo-Anne BScPharm, ACPR, PharmD

Lori Harwood, RN(EC), PhD (candidate), Nurse Practitioner, Hemodialysis, London Health Sciences Centre, London, ON

Lori Wazny, BScPharm, PharmD, Clinical Pharmacist, Manitoba Renal Program, Winnipeg, MB

Jo-Anne Wilson, BScPharm, ACPR, PharmD, Clinical Pharmacy Coordinator, Division of Nephrology, Department of Medicine, Capital Health; Associate Professor, College of Pharmacy, Dalhousie University, Halifax, Nova Scotia

Address Correspondence to: Lori Harwood RN(EC), PhD(candidate), Nurse Practitioner, London Health Sciences Centre, Victoria Hospital, Rm A2-335 800 Commissioners Road E London, ON N6A 4G5

E-mail:[email protected]

Submitted for publication: March 6, 2014

Accepted for publication in revised form: June 20, 2014

CANNT Journal 24(3):p 12-19, July-August-September 2014.

OBJECTIVES

After reading this article, the reader will be able to:

Define the recommended hemoglobin and iron target levels for people with Chronic Kidney Disease (CKD).
Compare and contrast currently available medications to manage anemia in patients with CKD.
Implement the anemia management guidelines into their clinical practice sites.

ABSTRACT

The management of anemia is important for health outcomes for people with chronic kidney disease (CKD). Global evidenced-based guidelines must be placed in the Canadian context to be relevant to guide practice. This paper summarizes the response of the Canadian Society of Nephrology to global anemia management guidelines in CKD and the implications for practice.